By Adria Calatayud Novartis's Sandoz generic-drugs unit has received approval from the U.S. Food and Drug Administration for biosimilar medicine Tyruko to.
Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.
On this episode of There Has to Be a Better Way?, co-hosts Zach Coseglia and Hui Chen talk to Antoine Ferrère, global head of behavioral and data science in the ethics.
By Adria Calatayud Novartis s Sandoz said Thursday that the European Medicines Agency has accepted its marketing-authorization application for biosimilar drug denosumab, which is indicated. | May 25, 2023
By Cecilia Butini Shares in Evotec rose in early trading on Wednesday after the German biotechnology company said its Seattle-based subsidiary Just-Evotec Biologics would enter into a. | May 10, 2023